PFEPFIZER INC
Pharmaceutical Preparations
- Revenue
- $62.6B
- 1.6% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $3.0B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear151% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear36% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $73.6B | $91.8B | $50.9B | $63.6B | $62.6B | 1.6% |
| Net income | $22.0B | $31.4B | $2.1B | $8.0B | $7.8B | 3.2% |
| Operating cash flow | $32.6B | $29.3B | $8.7B | $12.7B | $11.7B | 8.2% |
| Capex | $2.7B | $3.2B | $3.9B | $2.9B | $2.6B | 9.6% |
| Stock-based comp | $1.2B | $872M | $525M | $877M | $799M | 8.9% |
| Buybacks | $0 | $2.0B | $0 | $0 | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.